glp-1 drugs and parkinson's disease Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease | Journal of Biomedical Science Beyond insulin: The Intriguing role

So, we have seen successful GLP-1 drugs receive warnings years after being on the market for previously unknown side effects, in both an older and newer GLP-1 drugs

The future oral GLP-1 receptor agonists, incretin dual agonists, triple agonists, and other new oral metabolic products will become popular only if they prove themselves capable of producing sustained results in obesity disease, type 2 diabetes, hypertension, dyslipidemia, cardiovascular risks, and metabolic syndromes through their effectiveness and safety

[DOI] [PubMed] [Google Scholar] 37.De Bernardinis M, Violi V, Roncoroni L, Boselli AS, Giunta A, Peracchia A

In: ISPOR [Internet] 2025

Doctors are also watching for muscle loss , which can happen during fast weight loss